{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?page=36&sponsor=AstraZeneca",
    "query": {
      "sponsor": "AstraZeneca",
      "page": 36
    },
    "page_size": 10
  },
  "pagination": {
    "page": 36,
    "page_size": 10,
    "total_count": 1904,
    "total_pages": 191,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=37&sponsor=AstraZeneca&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=35&sponsor=AstraZeneca&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-31T07:03:30.566Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04585477",
      "title": "Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-small Cell Lung Cancer",
        "Non-small Cell Lung Cancer Stage I",
        "Non-small Cell Lung Cancer Stage II",
        "Non-small Cell Lung Cancer Stage III"
      ],
      "interventions": [
        {
          "name": "AVENIO ctDNA Surveillance Kit",
          "type": "DEVICE"
        },
        {
          "name": "Durvalumab",
          "type": "DRUG"
        },
        {
          "name": "Durvalumab (Imfinzi) alone or in combination with platinum-based chemotherapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "DRUG"
      ],
      "sponsor": "Stanford University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 80,
      "start_date": "2021-04-08",
      "completion_date": "2027-12-30",
      "has_results": false,
      "last_update_posted_date": "2026-10-30",
      "last_synced_at": "2026-10-31T07:03:30.566Z",
      "location_count": 1,
      "location_summary": "Stanford, California",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04585477"
    },
    {
      "nct_id": "NCT04686305",
      "title": "Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Locally Advanced or Metastatic Non-Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "T-DXd",
          "type": "DRUG"
        },
        {
          "name": "Durvalumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Pemetrexed",
          "type": "DRUG"
        },
        {
          "name": "Volrustomig",
          "type": "DRUG"
        },
        {
          "name": "Rilvegostomig",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 304,
      "start_date": "2021-03-09",
      "completion_date": "2027-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-04-13",
      "last_synced_at": "2026-10-31T07:03:30.566Z",
      "location_count": 13,
      "location_summary": "Duarte, California • Newport Beach, California • Orange, California + 10 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Santa Rosa",
          "state": "California"
        },
        {
          "city": "Westwood",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04686305"
    },
    {
      "nct_id": "NCT07754331",
      "title": "Study of the Effect of Haemodialysis on the Pharmacokinetics, Safety, and Tolerability of Balcinrenone/Dapagliflozin",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Kidney Failure"
      ],
      "interventions": [
        {
          "name": "Balcinrenone/dapagliflozin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 10,
      "start_date": "2026-08-06",
      "completion_date": "2026-10-06",
      "has_results": false,
      "last_update_posted_date": "2026-10-20",
      "last_synced_at": "2026-10-31T07:03:30.566Z",
      "location_count": 1,
      "location_summary": "Orlando, Florida",
      "locations": [
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07754331"
    },
    {
      "nct_id": "NCT03245541",
      "title": "Radiation Therapy in Combination With Durvalumab for People With Pancreatic Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Pancreatic Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "Durvalumab",
          "type": "DRUG"
        },
        {
          "name": "Stereotactic Ablative Body Radiotherapy (SABR)",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2020-08-14",
      "completion_date": "2027-09",
      "has_results": false,
      "last_update_posted_date": "2026-10-09",
      "last_synced_at": "2026-10-31T07:03:30.566Z",
      "location_count": 7,
      "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more",
      "locations": [
        {
          "city": "Basking Ridge",
          "state": "New Jersey"
        },
        {
          "city": "Middletown",
          "state": "New Jersey"
        },
        {
          "city": "Montvale",
          "state": "New Jersey"
        },
        {
          "city": "Commack",
          "state": "New York"
        },
        {
          "city": "Harrison",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03245541"
    },
    {
      "nct_id": "NCT00242372",
      "title": "GALLANT 9 Tesaglitazar vs. Placebo in Combination With Insulin",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Tesaglitazar 0.5",
          "type": "DRUG"
        },
        {
          "name": "Insulin at least 30 units/day",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 370,
      "start_date": "2004-08",
      "completion_date": "2006-03",
      "has_results": false,
      "last_update_posted_date": "2009-04-22",
      "last_synced_at": "2026-10-31T07:03:30.566Z",
      "location_count": 71,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Tuscson, Arizona + 68 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tuscson",
          "state": "Arizona"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Greenbrae",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00242372"
    },
    {
      "nct_id": "NCT03012477",
      "title": "CISPLATIN + AZD-1775 In Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Triple-negative Metastatic Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "AZD1775",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 34,
      "start_date": "2017-01-18",
      "completion_date": "2020-11-30",
      "has_results": true,
      "last_update_posted_date": "2021-11-23",
      "last_synced_at": "2026-10-31T07:03:30.566Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03012477"
    },
    {
      "nct_id": "NCT02053909",
      "title": "Ticagrelor Antiplatelet Therapy to Reduce Graft Events and Thrombosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Saphenous Vein Graft Disease"
      ],
      "interventions": [
        {
          "name": "Aspirin",
          "type": "DRUG"
        },
        {
          "name": "Ticagrelor",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boca Raton Regional Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 250,
      "start_date": "2014-09",
      "completion_date": "2021-08",
      "has_results": true,
      "last_update_posted_date": "2022-09-14",
      "last_synced_at": "2026-10-31T07:03:30.566Z",
      "location_count": 1,
      "location_summary": "Boca Raton, Florida",
      "locations": [
        {
          "city": "Boca Raton",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02053909"
    },
    {
      "nct_id": "NCT00588406",
      "title": "Study of Budesonide as an Addition to Standard Therapy in Adult Asthmatics in the Emergency Room.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "Budesonide",
          "type": "DRUG"
        },
        {
          "name": "albuterol",
          "type": "DRUG"
        },
        {
          "name": "Ipratropium bromide",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Northwell Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 95,
      "start_date": "2007-09",
      "completion_date": "2009-12",
      "has_results": true,
      "last_update_posted_date": "2016-01-21",
      "last_synced_at": "2026-10-31T07:03:30.566Z",
      "location_count": 3,
      "location_summary": "East Meadow, New York • Queens, New York • The Bronx, New York",
      "locations": [
        {
          "city": "East Meadow",
          "state": "New York"
        },
        {
          "city": "Queens",
          "state": "New York"
        },
        {
          "city": "The Bronx",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00588406"
    },
    {
      "nct_id": "NCT01486433",
      "title": "The Effect of Multiple Doses of Epanova® on the Multiple-Dose Pharmacokinetics of Simvastatin in Healthy Normal Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hypertriglyceridemia"
      ],
      "interventions": [
        {
          "name": "Simvastatin",
          "type": "DRUG"
        },
        {
          "name": "acetylsalicylic acid (ASA)",
          "type": "DRUG"
        },
        {
          "name": "omefas",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 52,
      "start_date": "2011-11",
      "completion_date": "2012-03",
      "has_results": false,
      "last_update_posted_date": "2015-04-30",
      "last_synced_at": "2026-10-31T07:03:30.566Z",
      "location_count": 1,
      "location_summary": "Tempe, Arizona",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01486433"
    },
    {
      "nct_id": "NCT03401385",
      "title": "First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hormone Receptor Positive Breast Cancer",
        "Triple Negative Breast Cancer",
        "Non-small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Datopotamab Deruxtecan (Dato-DXd)",
          "type": "DRUG"
        },
        {
          "name": "Steroid Containing Mouthwash",
          "type": "DRUG"
        },
        {
          "name": "Non-Steroid Containing Mouthwash",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Daiichi Sankyo Co., Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 890,
      "start_date": "2018-01-31",
      "completion_date": "2028-01-01",
      "has_results": false,
      "last_update_posted_date": "2026-09-01",
      "last_synced_at": "2026-10-31T07:03:30.566Z",
      "location_count": 13,
      "location_summary": "Los Angeles, California • Washington D.C., District of Columbia • Atlanta, Georgia + 7 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03401385"
    }
  ]
}